Dr. Oz was caught on a hot mic saying he'd ban abortion even in the cases of rape or incest.
I’ve always been consistent: I'll fight as hard as I can to protect women's reproductive freedom + codify abortion rights into federal law.
The choice in this election is clear.
Getting close to 700k followers 👀
I am NOT able to spend million$ of my own money on this campaign (like Dr. Oz). Sooo increasing our following here is truly an invaluable way to get our Message out.
RT + follow if you're ready to flip this Senate seat from 🔴 to 🔵
🙏🙏🙏
Need to know about the core elements of an EU-RMPs/US-REMS and associated templates? Register today for the #Safety Risk Management: A Focus on EU RMPs and US REMs @DrugInfoAssn Training Course. https://t.co/Z64PeAI9P5
Learn how to design, develop, and manage a quality system related to your #pharmacovigilance system in a virtual setting! For more information https://t.co/DeaDYsfgCO
Now is the time to register for #DIA's Virtual Training #Clinical Statistics for Nonstatisticians! Increase level of #statistical knowledge! The course addresses topics such as confidence intervals, hypothesis testing, trial designs, & noninferiority. https://t.co/yQmUAt1XT3
Attend @DrugInfoAssn virtual training course to learn FDA’s approach to regulation of combination products. Click here for more information and to register https://t.co/snpNoEHaMJ
#virtualtraining#combinationproducts#fda
Build a solid foundation in key concepts of #drugsafety and #pharmacovigilance throughout the medical product development lifecycle by attending an upcoming #dia Drug Safety and Pharmacovigilance Across the Product Lifecycle Training course in March. For…https://t.co/aSIPOjQBnd
Just jumping into the world of #regulatory affairs? Learn more about @DrugInfoAssn training course that focuses on #FDA regulations for the content, submission, and review of INDs/NDAs through an in-person training taught by reputable faculty. Learn more https://t.co/Uw9on5Ma06
Need to know how to conduct a #benefit-risk assessment and select tools to optimize benefit-risk balance? Attend #DIA training course in Philadelphia this October - https://t.co/SMIe8nRo19
Increase your level of #statistical knowledge so that collaborative efforts between yourself and #statisticians on clinical investigative teams can be improved. Attend this @DrugInfoAssn training hosted by a knowledgeable, well-informed instructor - https://t.co/HtDlw5ahPP
Register now to reserve your seat for @DrugInfoAssn#Safety and #Pharmacovigilance learning in Boston! This interactive course will help you identify the principles, seriousness, and regulatory framework for clinical trials and post-marketing safety. https://t.co/2uRrpDB92W
DIA is partnering with Yale University School of Public Health to offer a Statistics for Nonstatisticians course in April. Space is limited so register today to secure your spot. https://t.co/vOsDDBNx7E #dia#yale#training#lifesciences # #statistics
@DrugInfoAssn is partnering with Yale University School of Public Health to offer a Statistics for Nonstatisticians course in April. Space is limited so register today to secure your spot. https://t.co/vOsDDBNx7E #dia#yale#training#lifesciences
Need a refresher on #regulatory strategy? Learn more about #FDA regulations for the content, submission, and review of INDs/NDAs through an in-person training hosted by @DrugInfoAssn. Register now for the early bird rate https://t.co/BWjoKg2i9Y
First @DrugInfoAssn Drug Safety Training Course of 2019! Learn contemporary principles, regulatory expectations, and practical approaches to drug safety and #pharmacovigilance in key regulatory jurisdictions, with a focus on the US and EU. https://t.co/3zjuSJpJwH
Identify the history, principles, and regulatory framework for clinical trials and post-marketing #safety in this hands-on interactive @DrugInfoAssn training course: https://t.co/9ICvzN0aTM
Need a refresher on #regulatory strategy? Learn more about #FDA regulations for the content, submission, and review of INDs/NDAs through an in-person training hosted by @DrugInfoAssn https://t.co/BWjoKg2i9Y
New @DrugInfoAssn training course #Benefit-Risk Assessment and Management Across the Lifecycle. Participants will be able to apply the key concepts learned to conduct a benefit-risk assessment and select tools to optimize benefit-risk balance. Register at https://t.co/j1heuh2u6w